Shots:
- GSK will obtain an exclusive global license to HRS-9821, an add-on maintenance therapy for COPD, along with exclusive option rights to develop & commercialize ~11 more programs in oncology, respiratory, immunology, & inflammation globally (excl. mainland China, Hong Kong, Macau, & Taiwan for both)
- Each of the ~11 additional programs will have its own financial structure, with Hengrui leading P-I development incl. ex-China pts, & GSK holding opt-in & certain program substitution rights at or before P-I completion
- As per the deal, Hengrui will get $500M upfront across the agreements & ~$12B in development, regulatory & commercial milestones if all programmes are optioned, with tiered royalties on sales in GSK’s licensed areas
Ref: PRNewsWire| Image: GSK & Hengrui | Press Release
Related News:- GSK Receives Health Canada’s Approval for Blenrep (Belantamab Mafodotin) Regimens to Treat R/R Multiple Myeloma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
